These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 34849025)

  • 21. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.
    Mu Y; Xing P; Hao X; Wang Y; Li J
    Cancer Manag Res; 2019; 11():9243-9251. PubMed ID: 31802944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of afatinib in an NSCLC patient with
    Nozaki K; Watanabe S; Nishio K; Sakai K; Kikuchi T
    Transl Cancer Res; 2022 Jan; 11(1):295-298. PubMed ID: 35261905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
    Zhao Y; Liu J; Cai X; Pan Z; Liu J; Yin W; Chen H; Xie Z; Liang H; Wang W; Guo Z; Zhao S; Liang W; He J
    BMJ; 2019 Oct; 367():l5460. PubMed ID: 31591158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
    Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
    Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
    Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
    Hong W; Wu Q; Zhang J; Zhou Y
    Oncol Lett; 2019 Oct; 18(4):3887-3895. PubMed ID: 31516600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L).
    Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Ito K; Tsuchiya-Kawano Y; Tanaka K; Harada T; Nakatani Y; Miura S; Yokoyama T; Nakamura T; Izumi M; Nakamura A; Ikeda S; Takayama K; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    JTO Clin Res Rep; 2023 Dec; 4(12):100587. PubMed ID: 38046380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.
    Fukuhara T; Imai K; Nakagawa T; Igusa R; Yokota H; Watanabe K; Suzuki A; Morita M; Onodera R; Inoue A; Miura M; Minamiya Y; Maemondo M
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
    Sakata Y; Saito G; Sakata S; Oya Y; Tamiya M; Suzuki H; Shibaki R; Okada A; Yokoyama T; Matsumoto H; Otsuki T; Sato Y; Junji U; Tsukita Y; Inaba M; Ikeda H; Arai D; Maruyama H; Hara S; Tsumura S; Morinaga J; Sakagami T
    Lung Cancer; 2024 Feb; 188():107450. PubMed ID: 38160082
    [No Abstract]   [Full Text] [Related]  

  • 33. First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
    Lakkunarajah S; Truong PT; Bone JN; Hughesman C; Yip S; Alex D; Hart J; Pollock P; Egli S; Clarkson M; Lesperance M; Ksienski D
    Transl Lung Cancer Res; 2023 Jul; 12(7):1454-1465. PubMed ID: 37577326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Chihara Y; Takeda T; Goto Y; Nakamura Y; Tsuchiya-Kawano Y; Nakao A; Onoi K; Hibino M; Fukuda M; Honda R; Yamada T; Taniguchi R; Sakamoto S; Date K; Nagashima S; Tanzawa S; Minato K; Nakatani K; Izumi M; Shimose T; Kishimoto J; Uchino J; Takayama K
    Oncologist; 2022 Nov; 27(11):903-e834. PubMed ID: 36181763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.
    Igawa S; Fukui T; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Hisashi M; Sasaki J; Naoki K
    Invest New Drugs; 2022 Apr; 40(2):430-437. PubMed ID: 34807331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
    Zhou Q; Li J; Cang SD; Lin JX; Tu HY; Du Y; Qin JW; Liang XH; Yu Y; Lan HT; Shi HQ; Hua D; Liu SM; Wu YL
    Clin Lung Cancer; 2024 Sep; ():. PubMed ID: 39424513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
    Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of
    Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
    Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
    [No Abstract]   [Full Text] [Related]  

  • 39. A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with
    Igawa S; Kasajima M; Ono T; Ozawa T; Kakegawa M; Kusuhara S; Sato T; Nakahara Y; Fukui T; Yokoba M; Kubota M; Mitsufuji H; Sasaki J; Naoki K
    Cancer Manag Res; 2021; 13():8695-8705. PubMed ID: 34849025
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.